6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $42000 | -$11M | 0.0% | -27450.0% | -$7M | — | $7M |
| 2024 | $181000 | -$10M | 5.0% | -5295.6% | -$7M | — | $9M |
| 2023 | $0 | -$9M | — | — | -$7M | — | $11M |
| 2022 | $134000 | -$13M | 24.6% | -9714.2% | -$13M | — | $12M |
| 2021 | $571000 | -$12M | 34.7% | -2139.6% | -$9M | — | $25M |
| 2020 | $365000 | -$11M | 17.8% | -3059.7% | -$11M | — | $9M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $0 | -$4M | — | — | -$3M | — | $4M |
| Dec '25 | $0 | -$3M | — | — | -$2M | — | $7M |
| Sep '25 | $0 | -$3M | — | — | -$3M | — | $9M |
| Jun '25 | $0 | -$3M | — | — | -$2M | — | $11M |
| Mar '25 | $42000 | -$3M | 0.0% | -6102.4% | -$1M | — | $13M |
| Dec '24 | $82000 | -$2M | 0.0% | -2850.0% | -$1M | — | $9M |
| Sep '24 | $42000 | -$3M | 0.0% | -7192.9% | -$2M | — | $7M |
| Jun '24 | $57000 | -$2M | 15.8% | -3798.2% | -$1M | — | $9M |
| Mar '24 | $0 | -$2M | — | — | -$2M | — | $9M |
| Dec '23 | $0 | -$2M | — | — | -$3M | — | $11M |
| Sep '23 | $0 | -$2M | — | — | -$2M | — | $8M |
| Jun '23 | $0 | -$2M | — | — | -$2M | — | $9M |
| Mar '23 | $0 | -$2M | — | — | -$2M | — | $11M |
| Dec '22 | $14000 | -$3M | 42.9% | -21914.3% | -$2M | — | $12M |
| Sep '22 | $8000 | -$3M | 25.0% | -35812.5% | -$3M | — | $14M |
| Jun '22 | $44000 | -$3M | 25.0% | -7384.1% | -$3M | — | $17M |
| Mar '22 | $68000 | -$4M | 20.6% | -5639.7% | -$5M | — | $20M |
| Dec '21 | $165000 | -$4M | 17.6% | -2477.6% | -$3M | — | $25M |
| Sep '21 | $140000 | -$3M | 53.6% | -2300.0% | -$2M | — | $27M |
| Jun '21 | $109000 | -$3M | 9.2% | -2357.8% | -$2M | — | $27M |
How the market has priced ENTX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Entera Bio Ltd.'s revenue has declined 35.1% per year. These are computed facts, not advice.
As of FY2025, Entera Bio Ltd. reported — of total debt against $7M of cash.
In FY2025, gross margin was 0.0%, operating margin -27450.0%, and net margin -27235.7%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.